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INTRODUCTION: The present study examines cardiovascular risk factor profiles and 24-month mortality in patients with symp-
tomatic peripheral arterial disease.
DESIGN STUDY: Prospective observational study including 75 consecutive patients with PAD (67 ± 9.7 years of age; 52 men and 
23 women) hospitalized for planned peripheral vascular reconstruction. Doppler echocardiograms were performed before surgery in 
54 cases. Univariate analyses were performed using Student’s t-test or Fisher’s exact test. Survival analysis at 24-month follow-up 
was performed using the Cox regression model and Kaplan-Meier method including age and chronic use of aspirin as covariates. 
Survival curves were compared using the log-rank test. 
RESULTS: Hypertension and smoking were the most frequent risk factors (52 cases and 51 cases, respectively), followed by 
diabetes (32 cases). Undertreated dyslipidemia was found in 26 cases. Fasting glycine levels (131 ± 69.1 mg/dl) were elevated in 
29 cases. Myocardial hypertrophy was found in 18 out of 54 patients. Thirty-four patients had been treated with aspirin. Overall 
mortality over 24 months was 24% and was associated with age (HR: 0.064; CI95: 0.014-0.115; p=0.013) and lack of use of aspirin, 
as no deaths occurred among those using this drug (p<0.001). No association was found between cardiovascular death (11 cases) 
and the other risk factors. 
CONCLUSION: There is a high prevalence of uncontrolled (treated or untreated) cardiovascular risk factors in patients undergo-
ing planned peripheral vascular reconstruction, and chronic use of aspirin is associated with reduced all-cause mortality in these 
patients.
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INTRODUCTION
Peripheral arterial disease (PAD) is a progressive 
condition that results in vessel stenosis and obstruction of 
arterial blood flow exclusive to the coronary and intracranial 
vessels.1 Advanced age, smoking and diabetes (DM) are 
risk factors associated with PAD. Other risk factors include 
hypertension (AH), hyperlipidemia, gender (male), elevated 
glucose level, prior myocardial infarction (MI), heart 
failure, history of cerebrovascular events, and elevated 
plasma fibrinogen levels.2 As a manifestation of systemic 
atherosclerosis, PAD is a common condition associated with 
high morbidity and mortality. Left untreated, it increases 
the risk of heart attack, stroke, amputation, or death.3,4 
Because atherosclerosis overlaps in multiple circulatory 
subsystems, a high incidence of coronary artery disease and 
cerebrovascular disease has been shown in PAD patients.5,6 
It is well known that treatment of cardiovascular (CV) 
risk factors delays the progression of atherosclerosis, reduces 
cardiovascular events and improves survival and quality of 
life.7,8 Therefore, patients with PAD, as well as those with 
coronary artery disease (CAD), benefit from CV risk factor 
management.1,3,7 However, it seems that atherosclerosis risk 
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factors are less tightly controlled in PAD patients when 
compared to CAD patients.6,9,10 
To further address this issue, we examined patients 
with symptomatic PAD hospitalized for surgical vascular 
reconstruction. This study analyzed cardiovascular risk factor 
profiles and all-cause mortality over a 24 month period. 
We also evaluated cardiac alterations using conventional 
transthoracic Doppler-echocardiograms. 
METHODS
Study Design
All procedures were approved by the research ethics 
committee of our Institution. All participants gave written 
informed consent.
From March 2002 to October 2003, seventy-five 
consecutive patients admitted for planned surgical repair of 
PAD were prospectively included in the study. The initial 
vascular diagnoses were lower extremity ischemia (65 cases) 
or carotid stenosis (10 cases). 
Exclusion criteria were unstable hemodynamic conditions 
or request for an urgent surgical procedure. The primary 
endpoint was total mortality during the 24-month follow-
up. 
Patients were interviewed to assess smoking habits, 
AH, DM, dyslipidemia, and/or previous cerebrovascular 
events. A complete medical evaluation, including a standard 
12-lead EKG, was performed for each patient by the same 
cardiologist (SGZ). Blood pressure control goals were 
<140/90 mmHg, or 130/80 mmHg if the patient presented 
with diabetes or chronic kidney disease.11 
Blood cholesterol, triglycerides, fasting glucose, and 
creatinine levels were measured at hospital admission. Tests 
were performed by enzymatic reactions using kits from 
Johnson & Johnson, or dry chemistry methodology with a 
Vitros 750 auto-analyzer. Considering that this population 
is at high risk for cardiovascular events, the following 
target limits were set: total cholesterol <200 mg/dl; LDL-
cholesterol <100 mg/dl, triglycerides <150 mg/dl, and 
fasting glycine levels <126 mg/dl. 7 
Standard transthoracic echocardiograms were performed 
in 54 cases within the first 24 hours of hospitalization, 
before surgery, following the American Society of 
Echocardiography Committee recommendations for chamber 
quantification.12 Left ventricular (LV) mass was calculated, 
and systolic function was evaluated by ejection fraction 
(EF) and percentage of LV diameter fractional shortening 
(% FS). Diastolic function was evaluated by measuring 
transmitral flow peak velocities (E and A, cm/s), and E/A 
ratio. Increased normalized wall thickness was taken as an 
index of ventricular concentric remodeling if the myocardial 
mass was within the reference range.12
All-cause mortality during the 24-month follow-up was 
the primary endpoint for this study. Statistical analyses 
were conducted using SYSTAT (version 10.2), and p-values 
of <0.05 (two-sided) were considered significant. Mean, 
standard deviation and proportion are presented. Univariate 
analyses were performed using Student’s t-test or Fisher’s 
exact test. Survival analysis in the 24-month follow-up was 
performed using the Cox regression model and Kaplan-Meier 
method, including age and chronic aspirin use as covariates. 
Survival curves were compared by using a log rank test. 
RESULTS
Fifty-two men and 23 women (p<0.001), 67 ± 9.7 years 
of age, were included in this study. Systolic and diastolic 
blood pressure were 129 ± 18 mmHg and 81 ± 6 mmHg, 
respectively. Fasting glycine levels were 131 ± 69 mg/dl, 
total cholesterol 194 ± 51 mg/dl, LDL-cholesterol 123±46 
mg/dl, HDL-cholesterol 41 ± 13 mg/dl, triglycerides 150 
± 74 mg/dl and creatinine 1.16 ± 0.40 mg/dl. Arterial 
hypertension and current smoking were the most prevalent 
risk factors (52 cases and 51 cases, respectively), followed 
by diabetes (32 cases). Undertreated dyslipidemia was found 
in 52 cases. Fasting glycine levels (131 ± 69.1 mg/dl) were 
elevated in 29 cases. 
Fifteen patients presented a previous cardiovascular 
event and 12 had documented coronary artery disease. None 
underwent myocardial revascularization. The ankle-brachial-
index was obtained in 61 cases, including all patients with 
lower extremity ischemia (mean±SD: 0.41±0.25).
Doppler-echocardiograms revealed cardiac structural 
alterations in 32 of 54 patients. The main alterations included 
increased left atrium (LA) in 34 cases and myocardial 
hypertrophy or concentric remodeling in 23 cases. Diastolic 
dysfunction was found in 42 patients, but only one presented 
systolic dysfunction. Arterial blood pressure was similar 
in patients with or without left ventricular hypertrophy 
or concentric remodeling, and no association was found 
between these structural alterations and mortality. 
Follow-up was performed at 19.6 ± 8.15 months. There 
were 18 deaths in 24 months from cardiovascular events (11 
cases) or other causes (7 cases). The time of cardiovascular- 
or non-cardiovascular-related death was similar (5.8 ± 3.2 
and 5.9 ± 5.5 months, respectively; p=0.98). In-hospital 
death occurred in two cases: one patient died from sepsis 
and the other from myocardial infarction. Univariate 
analyses (Table 1) showed that deaths occurred more often 
in older patients (72 ± 8.1 vs. 66 ± 9.7 years old, p=0.02) 
and in those with longer hospital stays (27 ± 16 vs. 17 ± 
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10 days, p=0.006). Age, gender, AH, fasting glycine levels, 
dyslipidemia, creatinine and self-reported smoking were not 
associated with mortality. Overall mortality over 24 months 
was 24% and was correlated with age (HR: 0.064; CI95: 
0.014-0.115; p=0.013) as well as non-use of aspirin, as no 
deaths occurred among patients using this drug (p<0.001; 
Figure 1). 
DISCUSSION
The present study shows that despite a poor outcome, 
patients with PAD are undertreated for modifiable CV risk 
factors. This suggests that more appropriate management, 
including strategies to reduce this risk, should be provided. 
For instance, the majority of patients previously diagnosed 
with DM presented fasting glycine levels >110mg/dl. This 
lack of proper risk factor control was even more remarkable 
for LDL-cholesterol. These data are in agreement with 
previous reports describing the high prevalence of untreated 
risk factors related to PAD in asymptomatic, non-diagnosed 
patients or in patients with known conditions.5,9,10 
Although the mean blood pressure was not remarkably 
high, 21.3% of patients presented values above the optimal 
upper limit established for secondary prevention.11 However, 
it must be taken into account that these values only 
correspond to measurements obtained during the initial 
clinical evaluation; this could be misleading for conclusions 
about AH control in these patients. 
Smoking cessation is the single most important factor 
associated with the outcome of patients with intermittent 
claudication.13 However, a report from the American Lung 
Association revealed that only 34% of smokers attempt to 
quit per year, and only 2.5% of those who try to stop actually 
succeed14. In the present study 53.3% of the patients were 
current smokers, although all were referred to programs for 
smoking cessation. 
Twenty-five percent of patients examined by 
echocardiography presented LV myocardial hypertrophy. 
Notably, these patients showed similar SBP and DBP when 
compared to those without hypertrophy. This suggests that 
treatment of AH is not the only requirement for reversing 
myocardial remodeling, as has been previously reported.15 
It is also possible that in this population, altered LV mass 
was related to causes other than hypertension, including co-
morbidities such as diabetes and smoking.16,17 This alteration 
was associated with enlarged cardiac left chambers and 
decreased left ventricular EF.
It is well known that ventricular remodeling causes 
myocardial relaxation impairment and diastolic dysfunction. 
In turn, diastolic dysfunction promotes increased pressure 
in the LA, which is typically the first cardiac chamber to 
dilate in this condition. In the present study, it is reasonable 
to assume that LA enlargement was caused by ventricular 
diastolic dysfunction. However, it is important to note that 
aging is also associated with reduced myocardial relaxation, 
decreased ventricular compliance, and LA enlargement. 
A challenge in analyzing these data is how to differentiate 
age-related physiological dysfunction from that associated 
with diastolic heart failure. The latter condition presumes 
clinically detectable heart failure with preserved systolic 
function and impaired ventricular filling.18 None of our 
patients presented signs or symptoms of heart failure at 
rest. However, many were physically impaired due to 
Table 1 - All-cause mortality and clinical variables
death survival P value
gender (F/M) 7/11 16/41 0,39
Previous CV event (yes/no) 2/16 13/44 0,28
Diabetes mellitus (yes/no) 7/11 25/32 0,71
Age (years) 72±8.1 66±9.7 0,02
Fasting glycine (mg/dL) 118±64 136±70 0,36
LDL-C (mg/dL) 117±42 125±46 0,56
HDL-C (mg/dL) 39±9 41±14 0,75
TG (mg/dL) 123±47 158±78 0,11
Serum creatinine (mg/dL) 1.25±0.50 1.13±0.35 0,35
Use of aspirin (yes/no) 0/18 33/24 <0.001
Student´s t test or Fisher exact test
Figure 1 - Kaplan-Meier survival curves for participants under aspirin treat-
ment (solid line) versus subjects without aspirin (dashed line). Survival curve 
in the 24-month follow-up for all 75 patients with severe peripheral arterial 
disease is displayed by gray line
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intermittent claudication, preventing the clinical evaluation 
of exertion tolerance. Our findings suggest that Doppler-
echocardiograms should be considered as an additional exam 
for all individuals with severe PAD, even in the absence of 
reported dyspnea.
The high mortality over the 24-month follow-up in the 
present study is in agreement with other evaluations of 
patients with severe PAD.1 Eleven patients died from MI 
or cerebrovascular ischemia, suggesting that atherosclerotic 
arterial disease was present in more than one arterial segment. 
A previous study including one thousand PAD patients 
identified a 25% prevalence of CAD by routine coronary 
angiography performed before elective peripheral vascular 
surgery.19 Peripheral arterial disease was in an advanced stage 
in all patients included in the present study, which would 
explain the high frequency of cardiovascular risk factors. 
This is an important observation, since these severely ill 
patients had neglected treatment for secondary prevention. 
It is remarkable that no patients died among those who had 
been chronically treated with aspirin. The beneficial effect 
of this drug is well-known for secondary prevention of both 
cerebrovascular and cardiovascular events.
In conclusion, there is a high prevalence of uncontrolled 
(treated or untreated) cardiovascular risk factors in patients 
undergoing planned peripheral vascular reconstruction. 
However, chronic use of aspirin was associated with reduced 
all-cause mortality in these patients.
Study limitations
The present study included a small population with PAD 
from a single Brazilian center. This limitation may explain 
the failure to detect any association between previous 
cerebrovascular events or myocardial hypertrophy and 
mortality. These associations are well documented in the 
literature. On the other hand, we were able to show that this 
high-risk population has been undertreated for cardiovascular 
risk factor and that there is an important association between 
death and the lack of use of aspirin.
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